Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.44 |
| ▸ | MICA | Q29983 | 1/20 | 0.44 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900075 | 0.93 | MCHR1 (0.49) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL5750997 | 0.93 | MCHR1 (0.49) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL5750602 | 0.93 | MCHR1 (0.49) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL1900073 | 0.93 | MCHR1 (0.49) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL5749921 | 0.93 | MCHR1 (0.50) | MCHR1CNR2HSD17B2CNR1PPARG | |
| SCHEMBL5753372 | 0.90 | MCHR1 (0.48) | MCHR1KLRK1MICARAET1LDRD4 | |
| SCHEMBL5754521 | 0.90 | MCHR1 (0.48) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL5753359 | 0.90 | MCHR1 (0.48) | MCHR1KLRK1MICARAET1LDRD4 | |
| SCHEMBL5751737 | 0.89 | MCHR1 (0.44) | MCHR1CNR2KLRK1MICARAET1L | |
| SCHEMBL5752254 | 0.89 | MAPK14 (0.48) | MCHR1CNR2HSD17B2CNR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | MCHR1 1618/4885CNR2 485/4885KLRK1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.